While it is unclear if pre-existing antibodies to adenovirus vector will affect vaccine efficacy, it is possible that repeated vaccination using adenovirus-based vaccine either as a booster or as annual vaccination, if the need arises, will result in reduced efficacy due to vector immunity.
Sputnik V vaccine
COVID-19: Challenges in achieving herd immunity through vaccination
Where everyone is equally affected by COVID-19 disease, immunisation should be available to all when vaccines are ready. It is important to remember that vaccines are a tool to promote health equity. If the goal is to achieve herd immunity, we will need about 70% of the population to be covered. Breaking the chain of … Continue reading COVID-19: Challenges in achieving herd immunity through vaccination
It makes sense to bring people to the vaccine instead of taking COVID-19 vaccine to people in some settings: Gagandeep Kang
mRNA vaccines for COVID-19, such as the one developed by Moderna, requires ultralow temperature (-70-80 degree C) during storage. India never had this kind of storage requirement and building the infrastructure for ultracold storage requires considerable resources, as it needs not just the freezers, but also uninterrupted power supply, says Dr. Gagandeep Kang. The government … Continue reading It makes sense to bring people to the vaccine instead of taking COVID-19 vaccine to people in some settings: Gagandeep Kang
India’s potential participation in COVAX advance market commitment is under way: Trevor Mundel
With 11 COVID-19 vaccines having entered Phase-3 trials and six vaccines already approved for limited use, the next challenge is to support manufacturing and ensure that vaccines are accessible, affordable and available to all people. India is yet to agree to purchase COVID-19 vaccines through the COVAX Advance Market Commitment (AMC). Discussions about the terms … Continue reading India’s potential participation in COVAX advance market commitment is under way: Trevor Mundel
Scientists alert Lancet to ‘data inconsistencies’ in the Russian vaccine trial paper
A group of 16 scientists has written an open letter to Dr Richard Horton, editor of The Lancet and authors of the Russia's Sputnik V novel coronavirus vaccine trial paper, raising questions about the integrity of the data published in The Lancet on September 4. Just four days after the results of the Phase-1/2 trials … Continue reading Scientists alert Lancet to ‘data inconsistencies’ in the Russian vaccine trial paper
Russia’s coronavirus vaccine is safe, elicits immune responses in Phase-1/2 trials
Russia’s Sputnik V vaccines for novel coronavirus have been found to be safe for a period of 42 days and capable of inducing antibody responses in all the 42 participants within 21 days. But the Phase-1/2 trials were open, not randomised, did not have a control group, and included totally 76 participants. Russia’s Sputnik V … Continue reading Russia’s coronavirus vaccine is safe, elicits immune responses in Phase-1/2 trials
Science Chronicle 